Tarsus Pharmaceuticals Inc - רווח למניה אחת ב-12 החודשים האחרונים TARS

Inertia is becoming the gold standard for treating eye infections, ensuring a steady stream of profit. The high authority of Tarsus Pharmaceuticals (TARS) among physicians reinforces its status as an ophthalmology innovator. Sales momentum for blepharitis treatments is creating a powerful growth impulse. The YoY ttm growth in net income per share visualizes the speed of cash flow recovery, where -653.30 reflects the latest value of the metric.
tarsusrx.com - פילוחים אנליטיים ומדדי מפתח (TARS)

Tarsus Pharmaceuticals (TARS) management's drive toward operational profitability through the expansion of its innovative drug is directly reflected in the growth rates of earnings per share. Current EPS YoY TTM dynamics quantify the annual net income growth over the last 12 months, allowing investors to distinguish a temporary price dip from a systemic deterioration of financial health and assess the actual speed of business scaling.